SCHEMBL20189883

SCHEMBL20189883

Cc1cccc(NCC2CCNCC2(F)F)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAK1 Q13153 1/20 0.38
NPSR1 Q6W5P4 2/20 0.36
HSD17B10 Q99714 1/20 0.36
RAB9A P51151 2/20 0.36
NPC1 O15118 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CRHR1 P34998 1/20 0.36
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
KMT2A Q03164 3/20 0.34
ALDH1A1 P00352 2/20 0.34
CACNA1B Q00975 2/20 0.34
APBA1 Q02410 2/20 0.34
MAPK1 P28482 1/20 0.34
HTT P42858 1/20 0.34
IRAK4 Q9NWZ3 1/20 0.34
GRIN2B Q13224 1/20 0.34
MEN1 O00255 2/20 0.33
CCNT1 O60563 1/20 0.33
JAK2 O60674 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20189880 1.00 PAK1 (0.38) PAK1NPSR1HSD17B10RAB9ANPC1
Trifluoroacetic Acid SCHEMBL20189748 0.90 HRH4 (0.41) PAK1RAB9ANPC1CRHR1HCRTR1
SCHEMBL20189409 0.82 GRIN2B (0.45) PAK1GRIN2BJAK2JAK1
SCHEMBL20189406 0.82 GRIN2B (0.45) PAK1GRIN2BJAK2JAK1
SCHEMBL20189374 0.80 CXCR4 (0.39) ALDH1A1GRIN2B
SCHEMBL20189379 0.80 CXCR4 (0.39) ALDH1A1GRIN2B
SCHEMBL20189772 0.79 GOT1 (0.34)
SCHEMBL20189544 0.79 GRIN2B (0.41) PAK1RAB9ACRHR1HCRTR1GRIN2B
SCHEMBL20189541 0.79 GRIN2B (0.41) PAK1RAB9ACRHR1HCRTR1GRIN2B
SCHEMBL20189774 0.79 GOT1 (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3544610-A1 TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS Rugen Holdings (Cayman) Limited (KY) 2019-10-02 EP disclosed
WO-2018098128-A1 TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS RUGEN HOLDINGS (CAYMAN) LIMITED (KY) 2018-05-31 WO disclosed
WO-2018098128-A1 TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS RUGEN HOLDINGS (CAYMAN) LIMITED (KY) 2018-05-31 WO disclosed